Upregulation of angiotensin converting enzyme by atrial natriuretic peptide and cyclic GMP in human endothelial cells

Cardiovascular Research

Volumn 40, Issue 1, 1998, Pages 206-210

  Saijonmaa, Outi ^a,b   Fyhrquist, Frej ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b MINERVA FOUNDATION INSTITUTE FOR MEDICAL RESEARCH   (Finland)

Author keywords

Angiotensin converting enzyme; Atrial natriuretic peptide; Cyclic GMP; HUVEC; Phosphodiesterase inhibitors

Indexed keywords

ATRIAL NATRIURETIC FACTOR; CYCLIC GMP; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; ISOBUTYLMETHYLXANTHINE; LISINOPRIL; PHOSPHODIESTERASE INHIBITOR; RAMIPRILATE; UNCLASSIFIED DRUG; ZAPRINAST;

ARTICLE; CELL CULTURE; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME ASSAY; ENZYME REGULATION; ENZYME SYNTHESIS; HUMAN; HUMAN CELL; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

1-METHYL-3-ISOBUTYLXANTHINE; ATRIAL NATRIURETIC FACTOR; CELLS, CULTURED; CYCLIC GMP; DIPYRIDAMOLE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; ENZYME INHIBITORS; HUMANS; PEPTIDYL-DIPEPTIDASE A; PHOSPHODIESTERASE INHIBITORS; PROTEIN KINASE INHIBITORS; PURINONES; STIMULATION, CHEMICAL; THIONUCLEOTIDES; UMBILICAL VEINS; VASODILATOR AGENTS;

EID: 0032189695     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(98)00103-5     Document Type: Article

References (22)

1. [1] Skidgel R, Erdös E. Biochemistry of angiotensin I-converting enzyme. In: Robertson I, Nicholls G, editors. The renin-angiotensin system. London, New York: Gower Medical, 1993;1:10.1-10.10.
2. [2] Dzau V, Pratt R. Cardiac, vascular, and intrarenal renin-angiotensin systems in normal physiology and disease. In: Robertson I, Nicholls G, editors. The renin-angiotensin system. London, New York: Gower Medical, 1993;1:42.1-42.11.
3. [3] Chobanian AC, Haudenschild C, Nickerson C, Drago R. Antiatherogenic effect of captopril in the Watanabe heritable hyperlipidemic rabbit. Hypertension 1990;15:327-331.
4. [4] Dahlöf B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients - a metaanalysis of 109 treatment studies. Am J Hypertens 1992;5:95-110.
5. [5] Moncada S, Palmer R, Higgs E. NO: physiology, pathophysiology and pharmacology. Pharmacol Rev 1991;43:109-142.
6. [6] Horning B, Kohler C, Drexler H. Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans. Circulation 1997;95:1115-1118.
7. [7] Waeber B, Brunner H. Cardiovascular hypertrophy: role of angiotensin II. and bradykinin. J Cardiovasc Pharmacol 1996;27(suppl 2):S36-S40.
8. [8] Kawaguchi H, Sawa H, Yasuda H. Effect of endothelin on angiotensin converting enzyme activity in cultured pulmonary artery endothelial cells. J Hypertens 1991;9:171-174.
9. [9] Dasarathy Y, Lanzillo J, Fanburg B. Stimulation of bovine pulmonary artery endothelial cell ACE by dexamethasone: involvement of steroid receptors. Am J Physiol 1992;263(Lung Cell Mol Physiol 7):L645-L649.
10. [10] Kawaguchi H, Sawa H, Yasuda H. Mechanism of increased angiotensin-converting enzyme activity stimulated by platelet-activating factor. Biochim Biophys Acta 1990;1052:503-508.
11. [11] Fyhrquist F, Hortung L, Grönhagen-Riska C. Induction of angiotensin I-converting enzyme by captopril in cultured human endothelial cells. J Clin Endocr Metab 1982;55:783-786.
12. [12] Dasarathy Y, Fanburg B. Involvement of second messenger systems in stimulation of angiotensin converting enzyme of bovine endothelial cells. J Cell Physiol 1991;148:327-335.
13. [13] Watanabe K, Lam G, Keresztes R, Jaffe E. Lipopolysaccharides decrease angiotensin converting enzyme activity expressed by cultured human endothelial cells. J Cell Physiol 1992;150:433-439.
14. [14] Jaffe E, Nachman R, Becker C, Minick R. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J Clin Invest 1973;52:2745-2756.
15. [15] Fyhrquist F, Tikkanen I, Grönhagen-Riska C, Hortung L, Hichens M. Inhibitor binding assay for angiotensin converting enzyme. Clin Chem 1984;30:696-700.
16. [16] Jackson B, Cubela R, Johnston C. Characterization of angiotensin converting enzyme from rat tissue by radio-inhibitor binding studies. Clin Exp Pharmacol Physiol 1986;13:681-689.
17. [17] Tikkanen I, Fyhrquist F, Metsärinne K, Leidenius R. Plasma atrial natriuretic peptide in cardiac disease and during infusion in healthy volunteers. Lancet 1985;2:66-69.
18. [18] Leitman D, Andresen J, Catalano R, Waldman S, Tuan J, Murad F. Atrial natriuretic peptide binding, cross-linking, and stimulation of cyclic GMP accumulation and paniculate guanylate cyclase activity in cultured cells. J Biol Chem 1988;263:3720-3728.
19. [19] Kawaguchi H, Sawa H, Yasuda H. Effect of atrial natriuretic factor on angiotensin converting enzyme. J Hypertension 1990;8:749-753.
20. [20] Chen X, Catravas J. Neutrophil-mediated endothelial angiotensinconverting enzyme dysfunction: role of oxygen-derived free radicals. Am J Physiol 1993;265:L243-L249.
21. [21] Iwai N, Matsunaga M, Kita T, Tei M, Kawai T. Regulation of angiotensin converting enzyme activity in cultured human vascular endothelial cells. Biochem Biophys Res Commun 1987;149:1179-1185.
22. [22] Conti M, Jin C, Monaco L, Repaske D, Swinnen J. Hormonal regulation of cyclic nucleotide phosphodiesterases. Endocr Rev 1991;12:218-234.